UQCR11 Antibody

What is UQCR11 and why is it significant in mitochondrial research?

UQCR11 (ubiquinol-cytochrome c reductase, complex III subunit XI) is the smallest known component of Complex III in the mitochondrial respiratory chain, weighing approximately 6.6 kDa and consisting of 56 amino acids . Its significance stems from its critical role in oxidative phosphorylation, a fundamental energy-producing pathway in cells. The protein likely functions as a binding factor for the iron-sulfur protein within Complex III, which catalyzes electron transfer from dihydroquinone to cytochrome c, a crucial step in cellular respiration . Research on UQCR11 is essential for understanding mitochondrial dysfunction in various diseases, particularly those involving energy metabolism disorders.

How are UQCR11 antibodies validated for research applications?

Proper validation of UQCR11 antibodies requires a multi-step approach to ensure specificity and reliability. The gold standard for validation includes testing in cells or tissues where UQCR11 is knocked out or knocked down to confirm absence of signal, similar to the validation approach described for C9ORF72 antibodies . Additional validation methods include:

• Western blotting against recombinant protein at the expected molecular weight (6.6 kDa)

• Testing in multiple cell lines with known UQCR11 expression (such as HeLa and MCF-7 cells)

• Immunoprecipitation followed by mass spectrometry

• Comparing results across multiple antibodies targeting different epitopes

• Immunohistochemistry in positive control tissues (such as human heart tissue)

Researchers should carefully review validation data provided by manufacturers and consider performing their own validation experiments to ensure antibody specificity before conducting critical experiments.

What are the common applications for UQCR11 antibodies in mitochondrial research?

UQCR11 antibodies are employed across various experimental techniques to study mitochondrial function and respiratory chain complexes. Based on available technical information, the primary applications include:

The application should be selected based on the specific research question, with Western blotting being particularly valuable for quantitative analysis of mitochondrial complex expression in comparative studies .

How should researchers optimize Western blot protocols for detecting the small UQCR11 protein?

Detecting UQCR11 via Western blotting presents unique challenges due to its small size (6.6 kDa) . Methodological considerations for successful detection include:

• Gel Selection: Use high percentage (15-20%) polyacrylamide gels or specialized tricine-based systems designed for low molecular weight proteins.

• Transfer Optimization: Employ semi-dry transfer systems with reduced methanol concentration and shorter transfer times (15-30 minutes) to prevent the small protein from passing through the membrane.

• Membrane Selection: PVDF membranes with 0.2 μm pore size are preferable to standard 0.45 μm membranes for retaining small proteins.

• Blocking Parameters: Use 5% non-fat dry milk or BSA in TBS-T for 30-60 minutes at room temperature, as longer blocking times may reduce signal for small proteins.

• Antibody Dilution: Start with manufacturer's recommended dilution (typically 1:500-1:2000) and optimize based on signal-to-noise ratio.

• Enhanced Chemiluminescence: Use high-sensitivity detection reagents designed for low-abundance proteins.

• Loading Controls: Standard loading controls like β-actin (42 kDa) run at significantly different rates than UQCR11; consider low molecular weight loading controls like ubiquitin (8.5 kDa).

What cross-reactivity concerns should researchers address when selecting UQCR11 antibodies?

Cross-reactivity represents a significant concern in UQCR11 antibody selection, similar to issues observed with other mitochondrial proteins . To address potential cross-reactivity:

• Review vendor validation data with a critical eye, focusing on knockout/knockdown controls when available.

• Consider testing multiple antibodies from different manufacturers and comparing results.

• Use genetic approaches (siRNA, CRISPR-Cas9) to create UQCR11-deficient controls that can validate antibody specificity.

• Be aware that UQCR11 antibodies might cross-react with other small mitochondrial proteins, particularly other components of Complex III.

• Perform pre-absorption tests using recombinant UQCR11 protein to confirm specificity.

• For immunocytochemistry, include mitochondrial markers to confirm co-localization with expected mitochondrial distribution.

Remember that antibody reagents may bind to multiple proteins despite manufacturer claims, as demonstrated by studies on C9ORF72 antibodies where "not a single antibody reagent used in any of the published studies actually worked as advertised" .

What are the critical parameters for immunohistochemical detection of UQCR11 in tissue samples?

Successful immunohistochemical detection of UQCR11 requires optimization of several parameters:

• Fixation: 10% neutral buffered formalin is typically suitable, with fixation time optimized based on tissue thickness (generally 24-48 hours).

• Antigen Retrieval: Use TE buffer at pH 9.0 as the primary method, with citrate buffer at pH 6.0 as an alternative approach .

• Blocking: Include steps to block both endogenous peroxidase activity and non-specific binding sites.

• Antibody Dilution: Begin with a 1:20-1:200 dilution range as recommended , titrating to identify optimal concentration for your specific tissue.

• Incubation Conditions: Primary antibody incubation at 4°C overnight typically provides better results than shorter incubations at room temperature.

• Detection System: Use sensitive detection systems like polymer-based HRP systems rather than traditional ABC methods.

• Counterstaining: Keep nuclear counterstaining light to avoid obscuring mitochondrial staining patterns.

• Controls: Include both positive control tissue (human heart is recommended) and negative controls (primary antibody omission and ideally UQCR11-knockout tissue).

How can researchers effectively analyze UQCR11 interactions with other components of Complex III?

Investigating protein-protein interactions involving UQCR11 requires specialized approaches due to its small size and mitochondrial localization:

• Proximity Ligation Assay (PLA): This technique can visualize interactions between UQCR11 and other Complex III components in situ with high specificity and sensitivity. The method requires antibodies to both interaction partners raised in different species.

• Co-immunoprecipitation (Co-IP) with Crosslinking: Standard Co-IP may disrupt weak interactions; using membrane-permeable crosslinkers like DSP (dithiobis(succinimidyl propionate)) before cell lysis can preserve transient interactions.

• Blue Native PAGE: This non-denaturing electrophoresis technique preserves intact mitochondrial complexes, allowing analysis of UQCR11 incorporation into fully assembled Complex III.

• FRET Analysis: By tagging UQCR11 and potential binding partners with appropriate fluorophores, Förster resonance energy transfer can detect close interactions in living cells.

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS): This technique can map interaction interfaces between UQCR11 and other Complex III components by measuring changes in deuterium uptake when proteins interact.

• Mitochondrial Subfractionation: Careful separation of inner membrane, outer membrane, and matrix fractions can help localize UQCR11 and identify compartment-specific interaction partners.

What approaches can help troubleshoot inconsistent UQCR11 antibody results across experiments?

Inconsistent antibody performance represents a significant challenge in UQCR11 research. Systematic troubleshooting approaches include:

• Antibody Storage and Handling:

  • Aliquot antibodies upon receipt to minimize freeze-thaw cycles

  • Store at recommended temperature (typically -20°C)

  • Centrifuge before use to remove aggregates

• Sample Preparation Variables:

  • Standardize lysis buffers and conditions

  • Include protease inhibitors appropriate for mitochondrial proteins

  • Consider gentler lysis methods for maintaining mitochondrial integrity when relevant

• Experimental Controls:

  • Use positive control samples with confirmed UQCR11 expression (HeLa or MCF-7 cells)

  • Include molecular weight markers appropriate for small proteins

  • Consider running recombinant UQCR11 as a standard

• Protocol Standardization:

  • Document detailed protocols including lot numbers of all reagents

  • Control for variables like incubation times and temperatures

  • Use consistent imaging parameters for immunofluorescence

• Antibody Validation:

  • Test specificity using siRNA knockdown of UQCR11

  • Consider multiple antibodies targeting different epitopes

  • Verify results with orthogonal techniques when possible

How do post-translational modifications impact UQCR11 antibody detection and function?

Post-translational modifications (PTMs) can significantly affect antibody binding and protein function. For UQCR11:

• Known and Predicted PTMs:

  • Phosphorylation may occur on serine, threonine, or tyrosine residues

  • Acetylation of lysine residues may affect protein interactions

  • Ubiquitination might regulate protein turnover

• Impact on Antibody Detection:

  • Epitope masking: PTMs may physically block antibody binding sites

  • Conformational changes: Modifications can alter protein folding, affecting antibody recognition

  • Electrophoretic mobility shifts: Some PTMs alter protein migration in gels, changing apparent molecular weight

• Methodological Approaches:

  • Use phosphatase treatment to assess phosphorylation effects

  • Compare reducing vs. non-reducing conditions to evaluate disulfide contributions

  • Consider phospho-specific antibodies for studying functional regulation

  • Employ mass spectrometry to characterize PTM profiles

• Functional Significance:

  • Correlate PTM status with Complex III assembly and activity

  • Investigate PTM changes under stress conditions or disease states

  • Explore PTM interplay with protein-protein interactions

How should researchers design experiments to study UQCR11 in mitochondrial disease models?

Investigating UQCR11 in disease contexts requires careful experimental design:

• Model Selection:

  • Cell lines: Choose models with relevant metabolic phenotypes (e.g., neuronal, cardiac, or muscle cells for high-energy demand tissues)

  • Animal models: Consider tissue-specific knockout approaches rather than global deletion

  • Patient-derived materials: Primary cells or iPSC-derived cell types maintain disease-relevant genetic background

• Experimental Approaches:

  • Compare UQCR11 protein levels between control and disease samples using validated antibodies

  • Assess subcellular localization changes using immunofluorescence

  • Measure Complex III activity in parallel with UQCR11 expression

  • Evaluate mitochondrial morphology and network dynamics

• Technical Considerations:

  • Include appropriate age-matched controls for developmental or aging studies

  • Consider the impact of mitochondrial heteroplasmy in genetic mitochondrial diseases

  • Account for tissue-specific expression patterns when designing experiments

• Functional Readouts:

  • Oxygen consumption rate (OCR) measurements

  • ROS production assays

  • Mitochondrial membrane potential assessment

  • ATP production quantification

What are best practices for comparing results from different UQCR11 antibodies in research?

When using multiple antibodies to increase confidence in research findings:

How can researchers effectively validate knockdown or knockout models for UQCR11 functional studies?

Proper validation of genetic models is essential for reliable UQCR11 research:

• mRNA Level Verification:

  • qRT-PCR targeting multiple regions of the transcript

  • RNA-seq to assess global expression changes and potential compensatory mechanisms

  • Northern blotting for definitive transcript size confirmation in complex cases

• Protein Level Confirmation:

  • Western blotting with validated antibodies targeting different epitopes

  • Mass spectrometry-based proteomics for unbiased verification

  • Immunofluorescence to confirm cellular expression patterns

• Functional Validation:

  • Complex III activity assays to confirm functional impact

  • Respiration measurements to assess mitochondrial function

  • Rescue experiments by reintroducing UQCR11 to confirm phenotype specificity

• Controls and Considerations:

  • Include appropriate wild-type controls from the same genetic background

  • Generate multiple independent knockout/knockdown lines to control for off-target effects

  • Consider inducible systems to study acute vs. chronic loss of function

  • Evaluate potential compensatory mechanisms by related proteins

What quality control measures should be implemented when using UQCR11 antibodies across different studies?

Ensuring reproducibility in antibody-based research requires rigorous quality control:

• Antibody Characterization and Documentation:

  • Record complete antibody information: supplier, catalog number, lot number, host species, clonality

  • Document validation methods used (Western blot, immunoprecipitation, knockout controls)

  • Maintain detailed protocols for each application

• Standardized Experimental Procedures:

  • Establish consistent sample preparation protocols

  • Use standard positive controls in each experiment (e.g., HeLa or MCF-7 cells)

  • Include technical and biological replicates with appropriate statistical analysis

• Critical Controls:

  • No-primary-antibody controls to assess secondary antibody specificity

  • Isotype controls for monoclonal antibodies

  • Peptide competition assays to confirm specificity

  • When possible, include genetic models (knockdown/knockout) as negative controls

• Performance Monitoring:

  • Regularly test antibody performance against reference standards

  • Compare results between antibody lots

  • Maintain control charts for key antibody performance metrics

• Data Sharing Practices:

  • Deposit raw images in appropriate repositories

  • Share detailed protocols through platforms like protocols.io

  • Consider antibody validation reporting standards (RRID usage)

How can researchers integrate multi-omics approaches with antibody-based studies of UQCR11?

Combining antibody-based detection with other -omics technologies provides deeper insights:

• Integrative Experimental Design:

  • Collect samples for parallel analysis by multiple methods

  • Include appropriate controls for each technology platform

  • Consider temporal dynamics when designing multi-omics studies

• Complementary Approaches:

  • Proteomics: Validate antibody results with mass spectrometry-based quantification

  • Transcriptomics: Correlate protein levels with mRNA expression patterns

  • Metabolomics: Link UQCR11 abundance to metabolic pathway activities

  • Interactomics: Identify novel UQCR11 binding partners through affinity purification

• Data Integration Strategies:

  • Use computational approaches to correlate findings across platforms

  • Apply pathway analysis to contextualize UQCR11 function

  • Develop predictive models incorporating multiple data types

  • Visualize integrated datasets to identify patterns

• Validation of Multi-omics Findings:

  • Confirm key relationships with targeted experiments

  • Use orthogonal techniques to validate critical discoveries

  • Apply both antibody-dependent and antibody-independent methods